europcr2014 1.7

32
EuroPCR 25th annual meeting of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) Paris 20-23 May 2014

Upload: astrazenecaoz

Post on 19-Jun-2015

39 views

Category:

Health & Medicine


0 download

DESCRIPTION

Europcr2014 1.7

TRANSCRIPT

  • 1. EuroPCR25th annual meeting of theEuropean Association ofPercutaneous CardiovascularInterventions (EAPCI)Paris20-23 May 2014

2. EuroPCR 2014Paris20-23 May 2014Cardiac regeneration:Update for interventionalistsCommentary:Dr James ChongWestmead Hospital, Sydney 3. Date of preparation May 2014 BRI001132Disclaimer AstraZeneca abides by the Medicines Australia Code of Conduct (Edition 17) andAstraZeneca Global Policies, and as such will not engage in the promotion ofunregistered products or unapproved indications. These highlights have been suggested by a group of cardiologists who attendedEuroPCR 2014, compiled by an external medical writer and sponsored byAstraZeneca. AstraZeneca has obtained permission from EuroPCR, to utilise the selected content foreducational purposes. Statements of fact and opinions expressed are those of the speakers individually and,unless expressly stated to the contrary, are not the opinion or position of AstraZeneca.AstraZeneca does not endorse or approve, and assumes no responsibility for, thecontent, accuracy, or completeness of the information presented. Presentations areintended for educational purposes only and do not replace independent professionaljudgement. Please refer to the appropriate approved Product Information before prescribing anyagents mentioned in these highlights.AstraZeneca Pty Ltd, Alma Road, North Ryde 2113 ABN: 54 009 682 311 4. EuroPCR 2014Paris20-23 May 2014 5. EuroPCR 2014Paris20-23 May 2014 6. EuroPCR 2014Paris20-23 May 2014 7. EuroPCR 2014Paris20-23 May 2014 8. EuroPCR 2014Paris20-23 May 2014 9. EuroPCR 2014Paris20-23 May 2014 10. EuroPCR 2014Paris20-23 May 2014Acute STEMIProfessor Andreas ZeiherUniversity of Freiburg 11. EuroPCR 2014Paris20-23 May 2014BAMI studyThe Effect of Intracoronary Reinfusion of Bone Marrow-derivedMononuclear Cells (BM-MNC) on All Cause Mortality in AcuteMyocardial Infarction Multinational, multicentre, randomised open-label, controlled, parallel-groupphase III study. Aims to demonstrate that a single intracoronary infusion of autologousbone marrow-derived mononuclear cells is safe and reduces all-causemortality in patients with LVEF